Showing 2681-2690 of 3315 results for "".
- Replay Launches Its First HSV Gene Therapy Company, Eudora, Focused on Retinal Eye Diseasehttps://modernod.com/news/replay-launches-its-first-hsv-gene-therapy-company-eudora-focused-on-retinal-eye-disease/2481216/Replay announced the launch of Eudora, an HSV gene therapy company targeting genetic retinal diseases. It is the first of Replay’s product companies to leverage its high payload capacity herpes simplex virus (HSV) delivery vector, synHSV. Eudora’s co-founders, Professors Joe Glor
- Lori Tierney Joins Johnson & Johnson Vision as President of Americashttps://modernod.com/news/lori-tierney-joins-johnson-johnson-vision-as-president-of-americas/2481184/Johnson & Johnson Vision announced that Lori Tierney has joined the company as President of Americas. In this critical leadership role, Ms. Tierney will have full accountability for shaping the strategy and driving industry-leading growth of the vision care portfolio in both North America and
- Cellusion and Minaris Regenerative Medicine Enter Alliance for the Manufacturing of Corneal Endothelial Cell Regenerative Therapyhttps://modernod.com/news/cellusion-and-minaris-regenerative-medicine-enter-alliance-for-the-manufacturing-of-corneal-endothelial-cell-regenerative-therapy/2481170/Cellusion, a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem, and Minaris Regenerative Medicine, a global contract and development manufacturing organization, announced a Letter of Intent (LOI) of the Manufacturing of CLS001 for a cor
- TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for Glaucoma Drug Candidate TC-002https://modernod.com/news/tearclear-announces-positive-topline-results-from-clear-phase-3-study-for-the-treatment-of-glaucoma-with-tc-002-latanoprost-ophthalmic-solution-0005/2481165/TearClear announced that the company’s lead product, TC-002 (latanoprost ophthalmic solution 0.005%), met the primary and all secondary endpoints in the CLEAR phase 3 pivotal trial. With these results, TearClear plans to file a new drug application (NDA) with the FDA in
- Cellusion and Minaris Regenerative Medicine Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapyhttps://modernod.com/news/cellusion-and-minaris-regenerative-medicine-enter-into-business-alliance-for-the-manufacturing-of-cls001-for-a-corneal-endothelial-cell-regenerative-therapy/2481150/Cellusion, a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem, and Minaris Regenerative Medicine, a global contract and development manufacturing organization, announced a letter of intent (LOI) of the manufacturing of CLS001 for a cor
- Schwind Eye-Tech-Solutions Announces Management Changeshttps://modernod.com/news/schwind-eye-tech-solutions-announces-management-changes/2481149/Rolf Schwind, who was serving as CEO of Schwind eye-tech-solutions GmbH, has withdrawn from active leadership of the company, effective October 1, 2022, and joined the Advisory Board. In that capacity he will continue to contribute to the growth of Schwind with his more than 40 years of
- Haag-Streit to Host a Series of Educational Webinars as Part of its Biometry Focus Month in Novemberhttps://modernod.com/news/haag-streit-to-host-a-series-of-educational-webinars-as-part-of-its-biometry-focus-month-in-november/2481139/Haag-Streit will host a variety of educational webinars as part of its Biometry Focus Month in November. This series of webinars will be delivered by a distinguished faculty consisting of notable key opinion leaders, complemented by Haag-Streit biometry product specialists. Hosted on Zo
- Johnson & Johnson Vision Introduces Tecnis Symfony OptiBlue EDOF IOL, the Latest PC-IOL Powered by InteliLight Technologyhttps://modernod.com/news/johnson-johnson-vision-introduces-tecnis-symfony-optiblue-edof-iol-the-latest-pc-iol-powered-by-intelilight-technology/2481128/Johnson & Johnson Vision announced availability of a new presbyopia-correcting IOL (PC-IOL) powered by InteliLight technology, Tecnis Symfony OptiBlue IOL. This extended depth-of-focus (EDOF) lens expands presbyopia correction to more patients and joins Tecnis Synergy IOL, a hi
- Neurophth Announces First Patient Dosed in Phase 3 Clinical Trial for the Gene Therapy Treatment of LHONhttps://modernod.com/news/neurophth-announces-first-patient-dosed-in-phase-3-clinical-trial-for-the-gene-therapy-treatment-of-lhon/2481126/Neurophth Therapeutics announced that the first patient has been dosed in phase 3 clinical trial for the treatment of Leber hereditary optic neuropathy (LHON). Neurophth is conducting a phase 1/2/3, multicenter, two-part study aimed at evaluating the safety, tolerability, and effic
- EyeCare Partners Launches New Innovation Centerhttps://modernod.com/news/eyecare-partners-launches-new-innovation-center/2481118/EyeCare Partners (ECP) announced the launch of the EyeCare Partners Innovation Center, which aims to improve the delivery and quality of eye care and advance clinical eye health education. The Innovation Center will be led by ECP’s Chief Clinical Officer, Antonio Capone, Jr., MD.